SCHEMBL1650141

SCHEMBL1650141

CCc1c(CS(=O)(=O)c2ccccc2)ccc(C(=O)OC)c1-c1ccn(C)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
JMJD6 Q6NYC1 2/20 0.35
KMT2A Q03164 3/20 0.35
KDM4E B2RXH2 3/20 0.35
PTGDR2 Q9Y5Y4 2/20 0.35
POLB P06746 3/20 0.34
MEN1 O00255 1/20 0.34
SLC40A1 Q9NP59 1/20 0.33
TSHR P16473 1/20 0.33
PSMD14 O00487 1/20 0.33
MMP2 P08253 1/20 0.33
DNMT1 P26358 1/20 0.33
RECQL P46063 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
THRB P10828 1/20 0.33
MAPT P10636 1/20 0.33
PHGDH O43175 1/20 0.33
PTGES O14684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1648549 0.90 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2JMJD6KMT2AKDM4E
SCHEMBL1648266 0.87 LMNA (0.38) ALDH1A1SMN1; SMN2JMJD6KMT2APTGDR2
SCHEMBL1648529 0.78 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2JMJD6KMT2AKDM4E
SCHEMBL4912518 0.70 ALDH1A1 (0.53) ALDH1A1KMT2AKDM4EPOLBMEN1
SCHEMBL1649006 0.69 POLB (0.37) ALDH1A1SMN1; SMN2KMT2APOLBMAPT
SCHEMBL1648311 0.67 POLB (0.43) KMT2AKDM4EPOLBMEN1MAPT
SCHEMBL1649078 0.67 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2KMT2AKDM4EPOLB
SCHEMBL1648347 0.67 METAP2 (0.46) ALDH1A1KMT2APOLBL3MBTL1MAPT
SCHEMBL1648271 0.65 LRRK2 (0.43) ALDH1A1SMN1; SMN2KDM4E
SCHEMBL31555655 0.65 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2KMT2AKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-02-25 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
EP-2486004-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME Zafgen Corporation (US) 2012-08-15 EP disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, DNPEP, STS ALDH1A1 360/4885SMN1; SMN2 2123/4885JMJD6 611/4885
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same METAP2, DNPEP, STS ALDH1A1 360/4885SMN1; SMN2 2123/4885JMJD6 611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.